TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11815403

Group type: EXPERIMENTAL
Intervention: First-class mail
Number of subjects: 4999

Group type: COMPARATOR
Intervention: Bulk mail
Number of subjects: 4999

Group type: EXPERIMENTAL
Intervention: Including invitation letter
Number of subjects: 4999

Group type: EXPERIMENTAL
Intervention: Recruitment via mass mailings
Number of subjects: 4999
Study: 9831138

Group type: EXPERIMENTAL
Intervention: Tympanoplasty type II with ionomeric cement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tympanoplasty type II with titanium-gold-angle prosthesis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Incus interposition
Number of subjects: 45
Study: 7664508

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 20
Study: 2502734

Group type: EXPERIMENTAL
Intervention: Calcium mupirocin 2% nasal ointment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30814387

Group type: EXPERIMENTAL
Intervention: Arthrocentesis with lavage alone (A-group, n = 17)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Arthrocentesis with lavage and hyaluronic acid injection (AS-group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 40
Study: 26912531

Group type: EXPERIMENTAL
Intervention: Direct instruction of MDI technique from a pharmacist
Number of subjects: 72

Group type: COMPARATOR
Intervention: Reading a metered dose inhaler (MDI) package insert pamphlet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Watching a CDC video demonstrating MDI technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: Watching a YouTube video demonstrating MDI technique
Number of subjects: 72
Study: 26409153

Group type: EXPERIMENTAL
Intervention: Single-step time-lapse medium (G-TL)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sequential media (G-1/G-2)
Number of subjects: 128
Study: 23069838

Group type: EXPERIMENTAL
Intervention: GLP-1 with insulin
Number of subjects: 5

Group type: COMPARATOR
Intervention: GLP-1 with saline
Number of subjects: 5

Group type: COMPARATOR
Intervention: GLP-1 with vitamin C
Number of subjects: 5

Group type: COMPARATOR
Intervention: GLP-1(9-36) during hyperinsulinemia
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 5
Study: 21596077

Group type: EXPERIMENTAL
Intervention: PCV7 (1 ×)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: PCV7+PCV9 (2 ×)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: 2 × PCV7 + 2 × PCV9 (4 ×)
Number of subjects: 443

Group type: COMPARATOR
Intervention: PPV (Control)
Number of subjects: 443
Study: 19834342

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8945

Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 8945
Study: 16938694

Group type: EXPERIMENTAL
Intervention: Increasing the number of associates studied
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing backward associative strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing study item presentation frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing study time
Number of subjects: 0
Study: 15239094

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b (1.5 microg/kg per week) and ribavirin (1000‐1200 mg/day) for 24 or 48 weeks depending on HCV genotype
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no opioid maintenance)
Number of subjects: 100
Study: 11288040

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (wild-type allele)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (defective allele)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Atorvastatin and Bezafibrate
Number of subjects: 116
Study: 9303339

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg b.i.d.) for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oral prednisolone (PSL, 5-15 mg/day)
Number of subjects: 22
Study: 8287653

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load of 10 cm H2O
Number of subjects: 7

Group type: COMPARATOR
Intervention: Free breathing
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hypercapnic rebreathing
Number of subjects: 7
Study: 3327703

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 200 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31248973

Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide-dexamethasone (Rd-R)
Number of subjects: 474
Study: 29396374

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice daily for 24 months
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 27501597

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.1 mg orally
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (oral corn starch)
Number of subjects: 165
Study: 25749406

Group type: EXPERIMENTAL
Intervention: Proportion of Negative Reviews
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Position of Negative Reviews
Number of subjects: 500

Group type: COMPARATOR
Intervention: Cognitive Elaboration
Number of subjects: 500
Study: 23768747

Group type: EXPERIMENTAL
Intervention: Boceprevir (800 mg three times per day) plus peginterferon (1.5 μg/kg per week) and ribavirin (600-1400 mg per day) for 44 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo plus peginterferon (1.5 μg/kg per week) and ribavirin (600-1400 mg per day) for 44 weeks
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Boceprevir (800 mg three times per day) plus peginterferon-ribavirin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo plus peginterferon-ribavirin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon-ribavirin
Number of subjects: 99
Study: 20870230

Group type: EXPERIMENTAL
Intervention: Counseling through oral presentations on menopause and HT (n=64)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (n=63)
Number of subjects: 125
Study: 18270769

Group type: EXPERIMENTAL
Intervention: Ropivacaine infusion at the beginning of LC plus normal saline infusion at the end (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ropivacaine infusion at the beginning of LC (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (Group F)
Number of subjects: 120
Study: 16855196

Group type: EXPERIMENTAL
Intervention: Cognitive intervention emphasizing comparison of experienced outcomes with expectation of ideal outcomes
Number of subjects: 331

Group type: COMPARATOR
Intervention: Cognitive intervention emphasizing comparison of experienced outcomes with pretreatment status
Number of subjects: 331
Study: 12529346

Group type: EXPERIMENTAL
Intervention: Behavioral intervention promoting a low-fat diet
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 286
Study: 10423655

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg intravenous dolasetron
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.8 mg/kg intravenous dolasetron
Number of subjects: 21
Study: 8899321

Group type: EXPERIMENTAL
Intervention: Ukrain
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no Ukrain)
Number of subjects: 15
Study: 1897345

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg.kg‐1 followed by suxamethonium 1.5 mg.kg‐1 in E1uE1a patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Suxamethonium 1.5 mg.kg‐1 without pretreatment in E1uE1a patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg.kg‐1 followed by suxamethonium 1.5 mg.kg‐1 in E1uE1u patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Edrophonium injection
Number of subjects: 43
Study: 6407503

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-300 mg daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Chlorimipramine (50-150 mg daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150-300 mg three times daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Chlorimipramine (150-300 mg three times daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 73
Study: 31416344

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study: 29895378

Group type: EXPERIMENTAL
Intervention: Anti-rheumatic treatment (methotrexate monotherapy or anti-TNF therapy with or without methotrexate)
Number of subjects: 130
Study: 28391661

Group type: EXPERIMENTAL
Intervention: 8% strontium acetate dentifrice with 1040 ppm fluoride as sodium fluoride
Number of subjects: 135

Group type: COMPARATOR
Intervention: Commercially available regular fluoride dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (negative control)
Number of subjects: 135
Study: 24103221

Group type: EXPERIMENTAL
Intervention: Cryoablation with a single Arctic Front balloon (23 or 28 mm) per patient and two 300-second applications per PV
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open‐irrigated radiofrequency catheters with Lasso and Navistar ThermoCool catheters and the CARTO system
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Complete PV conduction block at the end of the procedure
Number of subjects: 50
Study: 22101200

Group type: EXPERIMENTAL
Intervention: Hands-only cardiopulmonary resuscitation (HO-CPR)
Number of subjects: 863

Group type: COMPARATOR
Intervention: 30:2 cardiopulmonary resuscitation (30:2 CPR)
Number of subjects: 863
Study: 20800986

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate (APC) used in ACL reconstruction (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no APC used, group B)
Number of subjects: 50
Study: 18533739

Group type: EXPERIMENTAL
Intervention: Early GP IIb/IIIa inhibition in patients undergoing PCI for STEMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with fibrinolytics and GP IIb/IIIa inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive approach
Number of subjects: 0
Study: 17072072

Group type: EXPERIMENTAL
Intervention: Strength and endurance training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 33
Study: 14507107

Group type: EXPERIMENTAL
Intervention: Scholl Flight Socks (14-17 mmHg of pressure at the ankle)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 224
Study: 10720541

Group type: EXPERIMENTAL
Intervention: Live, attenuated, cold-adapted, trivalent influenza vaccine administered by nasal spray
Number of subjects: 0
Study: 8725709

Group type: EXPERIMENTAL
Intervention: Two-step warfarin regimen beginning 10-14 days pre-operatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin beginning the night before surgery
Number of subjects: 0
Study: 1559048

Group type: EXPERIMENTAL
Intervention: Four-session social learning based AIDS/drug injection prevention program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 104
Study: 3889071

Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with a gingivectomy procedure
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with an apically repositioned flap procedure without bone recontouring
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with an apically repositioned flap procedure including bone recontouring
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with a modified Widman flap procedure without bone recontouring
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with a modified Widman flap procedure including bone recontouring
Number of subjects: 16
Study: 30796851

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) over 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) in before-and-after design
Number of subjects: 48
Study: 30607117

Group type: EXPERIMENTAL
Intervention: San Huang decoction (shd), taken twice daily for 1 day before surgery and for 7 days postoperatively.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo, taken twice daily for 1 day before surgery and for 7 days postoperatively.
Number of subjects: 30
Study: 27501003

Group type: EXPERIMENTAL
Intervention: TORAYLIGHT NV (NV) dialyzer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional polysulfone (Con) dialyzer
Number of subjects: 20
Study: 24597798

Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs (3.4 g/day EPA and DHA ethyl‐esters)
Number of subjects: 0
Study: 22728519

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPPT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPPT) with alendronate
Number of subjects: 53

Group type: COMPARATOR
Intervention: Methylprednisolone pulse therapy (MPPT) without alendronate
Number of subjects: 53
Study: 20669265

Group type: EXPERIMENTAL
Intervention: Once-daily extended-release (ER) pramipexole
Number of subjects: 156

Group type: COMPARATOR
Intervention: Immediate-release (IR) pramipexole
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both formulations (ER and IR)
Number of subjects: 156
Study: 17963457

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (2004-2005 or 2005-2006)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (17 healthy volunteers)
Number of subjects: 14
Study: 16255010

Group type: EXPERIMENTAL
Intervention: 7.5 mg/day prednisolone
Number of subjects: 250

Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 250
Study: 11097313

Group type: EXPERIMENTAL
Intervention: Pharmacia CAP specific IgE
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Specific IgE to 19‐kDa allergens
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IgE binding to 24‐kDa, 16‐kDa, and 9‐kDa allergens
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Periodate oxidation
Number of subjects: 34
Study: 9354308

Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral and Neoplanta capsules, single dose of 175 mg
Number of subjects: 24
Study: 8442966

Group type: EXPERIMENTAL
Intervention: Prophylactic epidural saline (40 to 60 ml)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Autologous blood (15 ml) via epidural catheter
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fluids and analgesics (control group)
Number of subjects: 74
Study: 3531034

Group type: EXPERIMENTAL
Intervention: Fentonium bromide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28937147

Group type: EXPERIMENTAL
Intervention: Conbercept 0.5 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 180
Study: 27388878

Group type: EXPERIMENTAL
Intervention: Self-management intervention provided by a trained community psychiatric nurse, followed by referral to primary care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group (long-term supportive contacts with a community psychiatric nurse and pharmacological management by a psychiatrist).
Number of subjects: 0
Study: 24189763

Group type: EXPERIMENTAL
Intervention: LD-1227
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 76
Study: 21575998

Group type: EXPERIMENTAL
Intervention: Isocaloric diet replacing saturated fat with monounsaturated fat (MUFA) by adding macadamia nuts
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Isocaloric diet replacing saturated fat with monounsaturated fat (MUFA)
Number of subjects: 64
Study: 18499435

Group type: EXPERIMENTAL
Intervention: Combination of plain and hyperbaric bupivacaine (5mg each)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (10mg)
Number of subjects: 72
Study: 16599830

Group type: EXPERIMENTAL
Intervention: Mixed fruit and vegetable juice powder concentrate, twice daily for 30 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (non-smokers)
Number of subjects: 32
Study: 14535973

Group type: EXPERIMENTAL
Intervention: Antithyroid therapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Plasma total homocysteine
Number of subjects: 182
Study: 11009241

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (40 microg/h) with bupivacaine 0.125% (8 mL/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Plain bupivacaine (without epinephrine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 24
Study: 9284763

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg p.o. 4 h before and 250 mg p.o. 1 h before GHRH
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1607256

Group type: EXPERIMENTAL
Intervention: Ketanserin + Aspirin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 23
Study: 3523718

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) and Sulfamethoxazole (SMZ) 160 mg/800 mg twice daily for five days
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) 200 mg twice daily for five days
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bicozamycin 500 mg four times a day for three days
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Furazolidone 100 mg four times a day for five days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (for TMP-SMZ and TMP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (for bicozamycin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (for furazolidone and ampicillin)
Number of subjects: 37
Study: 29652042

Group type: EXPERIMENTAL
Intervention: Mechanotherapeutic system training with VR feedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Task-oriented motor training with arm weight support and visual feedback
Number of subjects: 30
Study: 27459273

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 50
Study: 25015735

Group type: EXPERIMENTAL
Intervention: Fermented red ginseng (FRG), 3 times per day for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22646240

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20836956

Group type: EXPERIMENTAL
Intervention: 1-visit indirect pulp therapy (IPT)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 2-visit indirect pulp therapy (IPT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Direct complete excavation (DCE)
Number of subjects: 154
Study: 18671816

Group type: EXPERIMENTAL
Intervention: Everolimus 6 mg/day
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Azathioprine 2.5 mg/kg/day
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 20516539

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 183

Group type: COMPARATOR
Intervention: Cabergoline
Number of subjects: 183
Study: 16278786

Group type: EXPERIMENTAL
Intervention: Exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 12
Study: 11897445

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9592448

Group type: EXPERIMENTAL
Intervention: Music intervention in the PACU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 0
Study: 7837151

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control population (not specified)
Number of subjects: 16
Study: 3495505

Group type: EXPERIMENTAL
Intervention: Metronidazole as an adjuvant radiosensitizer
Number of subjects: 0

Group type: COMPARATOR
Intervention: No metronidazole treatment (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 0
Study: 30595325

Group type: EXPERIMENTAL
Intervention: School-based surveillance intervention
Number of subjects: 883

Group type: COMPARATOR
Intervention: Control arm (no school-based surveillance)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 883

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 883
Study: 27998277

Group type: EXPERIMENTAL
Intervention: GP training in recovery-oriented practice
Number of subjects: 18
Study: 24112306

Group type: EXPERIMENTAL
Intervention: Information plus one, two, or three commitment-enhancing BCTs (public self-commitment, implementation intentions, reminders)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Information only
Number of subjects: 340
Study: 22858061

Group type: EXPERIMENTAL
Intervention: Primary posterior continuous curvilinear capsulorrhexis (CCC) with posterior optic buttonholing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional in‐the‐bag implantation
Number of subjects: 20
Study: 20430261

Group type: EXPERIMENTAL
Intervention: rhNRG‐1 (0.6 microg/kg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 18495436

Group type: EXPERIMENTAL
Intervention: Ziprasidone IM 2 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ziprasidone IM 20 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ziprasidone IM
Number of subjects: 79
Study: 16157918

Group type: EXPERIMENTAL
Intervention: BTX‐B
Number of subjects: 0

Group type: COMPARATOR
Intervention: BTX‐A
Number of subjects: 0